Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 9, 2003. The report serves as a notification of changes in directors' interests in the company's Ordinary Shares and does not contain a full financial statement or operational update.
Key Financial Metrics
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction details.
Material Changes
The filing reports the following specific transactions regarding share ownership:
- GSK Trust Purchase: On January 7, 2003, Abacus (GSK) Trustees Limited purchased 11,345 Ordinary Shares at a price of £11.93 per share. This trust benefits current and former employees.
- Director Interest Increase: On January 8, 2003, Dr. J-P Garnier increased his interest by 252,609 Ordinary Share ADRs. This increase resulted from the reinvestment of dividends paid on January 3, 2003, at an average price of $38.358 per share.
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary, risks, contingencies, or unusual items. It is a routine disclosure of director shareholding changes.
Key Facts for Investor Verification
- Verify the total number of shares held by the GSK Trust following the January 7 purchase.
- Confirm the updated total shareholding of Dr. J-P Garnier after the dividend reinvestment.
- Note that the share price of £11.93 and ADR price of $38.358 reflect transaction values on specific dates in early January 2003.